Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.

Moore A, Stav I, Den RB, Gordon N, Sarfaty M, Neiman V, Rosenbaum E, Goldstein DA.

J Oncol. 2019 Jan 2;2019:8170428. doi: 10.1155/2019/8170428. eCollection 2019.

2.

A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.

Reinhorn D, Sarfaty M, Leshno M, Moore A, Neiman V, Rosenbaum E, Goldstein DA.

Oncologist. 2019 Feb 1. pii: theoncologist.2018-0656. doi: 10.1634/theoncologist.2018-0656. [Epub ahead of print]

PMID:
30710066
3.

Association Between Reimbursement Incentives and Physician Practice in Oncology: A Systematic Review.

Mitchell AP, Rotter JS, Patel E, Richardson D, Wheeler SB, Basch E, Goldstein DA.

JAMA Oncol. 2019 Jan 3. doi: 10.1001/jamaoncol.2018.6196. [Epub ahead of print]

PMID:
30605222
4.

Partial Scleral Rupture Presenting 4 Years After Laser in Situ Keratomileusis.

LaMattina KC, Feder RS, Koreishi AF, Goldstein DA.

Cornea. 2018 Dec 28. doi: 10.1097/ICO.0000000000001850. [Epub ahead of print]

PMID:
30601290
5.

Moving From Syndromic Description to Etiologic Diagnosis for Uveitis.

Leveque TK, Goldstein DA.

JAMA Ophthalmol. 2018 Dec 27. doi: 10.1001/jamaophthalmol.2018.6202. [Epub ahead of print] No abstract available.

PMID:
30589924
6.

Patient-Centered Oncology or Population-Centered Oncology-Which Do We Want, and Which Tradeoffs Are We Willing To Accept?

Goldstein DA, Den RB.

Oncologist. 2018 Dec 6. pii: theoncologist.2018-0679. doi: 10.1634/theoncologist.2018-0679. [Epub ahead of print] No abstract available.

PMID:
30523149
7.

Vertical Hyperreflective Lesions on Optical Coherence Tomography in Vitreoretinal Lymphoma.

Deák GG, Goldstein DA, Zhou M, Fawzi AA, Jampol LM.

JAMA Ophthalmol. 2018 Nov 29. doi: 10.1001/jamaophthalmol.2018.5835. [Epub ahead of print]

PMID:
30489610
8.

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.

Shlomai A, Leshno M, Goldstein DA.

PLoS One. 2018 Nov 8;13(11):e0207132. doi: 10.1371/journal.pone.0207132. eCollection 2018.

9.

Duration of adjuvant immunotherapy-biologic, clinical and economic considerations.

Stav I, Gyawali B, Goldstein DA.

Med Oncol. 2018 Oct 29;35(12):160. doi: 10.1007/s12032-018-1218-0.

PMID:
30374666
10.

Information Transparency in the Drug Approval Process-Reply.

Gyawali B, Goldstein DA.

JAMA Oncol. 2018 Nov 1;4(11):1622. doi: 10.1001/jamaoncol.2018.4163. No abstract available.

PMID:
30193359
11.

The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis.

Agrawal R, Gunasekeran DV, Agarwal A, Carreño E, Aggarwal K, Gupta B, Raje D, Murthy SI, Westcott M, Chee SP, McCluskey P, Ling HS, Teoh S, Cimino L, Biswas J, Narain S, Agarwal M, Mahendradas P, Khairallah M, Jones N, Tugal-Tutkun I, Babu K, Basu S, Lee R, Al-Dhibi H, Bodaghi B, Invernizzi A, Goldstein DA, Herbort CP, Barisani-Asenbauer T, González-López JJ, Androudi S, Bansal R, Moharana B, Mahajan S, Esposti S, Tasiopoulou A, Nadarajah S, Agarwal M, Abraham S, Vala R, Lord J, Singh R, Sharma A, Sharma K, Zierhut M, Kon OM, Kempen J, Cunningham ET, Rousselot A, Nguyen QD, Pavesio C, Gupta V.

Ocul Immunol Inflamm. 2018 Aug 29:1-11. doi: 10.1080/09273948.2018.1489061. [Epub ahead of print]

PMID:
30156979
12.

Time Is Money: Optimizing the Scheduling of Nivolumab.

Ratain MJ, Goldstein DA.

J Clin Oncol. 2018 Aug 27:JCO1800045. doi: 10.1200/JCO.18.00045. [Epub ahead of print] No abstract available.

PMID:
30148658
13.

Improving on Tail-of-the-Curve Evaluation With the American Society of Clinical Oncology Value Framework-Reply.

Ben-Aharon O, Goldstein DA.

JAMA Oncol. 2018 Oct 1;4(10):1438-1439. doi: 10.1001/jamaoncol.2018.3295. No abstract available.

PMID:
30128500
14.

The Influence of Race and Sex on the Side Effect Profile of Methotrexate in the Treatment of Uveitis.

LaMattina KC, Escott SM, Malalis JF, Mai D, Harada Y, Goldstein DA.

Ocul Immunol Inflamm. 2018 Aug 13:1-5. doi: 10.1080/09273948.2018.1498905. [Epub ahead of print]

PMID:
30102096
15.

A real-world analysis of cancer drug wastage due to oversized vials.

Liran O, Prus J, Gordon N, Almog V, Gruenewald T, Goldstein DA.

J Am Pharm Assoc (2003). 2018 Nov - Dec;58(6):643-646. doi: 10.1016/j.japh.2018.06.004. Epub 2018 Jul 13.

PMID:
30017368
16.

Tuberculous Uveitis Presenting with a Bullous Exudative Retinal Detachment: A Case Report and Systematic Literature Review.

Song JH, Koreishi AF, Goldstein DA.

Ocul Immunol Inflamm. 2018 Jul 3:1-12. doi: 10.1080/09273948.2018.1485958. [Epub ahead of print]

PMID:
29969330
17.

"Reversible Parkinsonism" following glyphosate exposure.

Goldstein DA, Dunn SE, Karberg K.

Parkinsonism Relat Disord. 2018 Nov;56:107. doi: 10.1016/j.parkreldis.2018.06.012. Epub 2018 Jun 6. No abstract available.

PMID:
29903583
18.

Denosumab for bone lesions in multiple myeloma - what is its value?

Goldstein DA.

Haematologica. 2018 May;103(5):753-754. doi: 10.3324/haematol.2017.185264. No abstract available.

19.

Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.

Sarfaty M, Hall PS, Chan KKW, Virik K, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA.

Eur Urol. 2018 Jul;74(1):57-62. doi: 10.1016/j.eururo.2018.03.006. Epub 2018 Mar 22.

PMID:
29576265
20.

The US Food and Drug Administration's Approval of Adjuvant Sunitinib for Renal Cell Cancer: A Case of Regulatory Capture?

Gyawali B, Goldstein DA.

JAMA Oncol. 2018 May 1;4(5):623-624. doi: 10.1001/jamaoncol.2017.5697. No abstract available.

PMID:
29522146
21.

Relapse of Juvenile Idiopathic Arthritis-Associated Uveitis after Discontinuation of Immunomodulatory Therapy.

Acharya NR, Patel S, Homayounfar G, Enanoria WTA, Shakoor A, Chakrabarti A, Goldstein DA.

Ocul Immunol Inflamm. 2018 Feb 16:1-7. doi: 10.1080/09273948.2018.1424341. [Epub ahead of print]

PMID:
29451845
22.

Early Steps in the Value of Cancer Care-Many Paths Remain Unexplored.

Goldstein DA, La Vecchia C, Goulart BHL.

Oncologist. 2018 Apr;23(4):391-392. doi: 10.1634/theoncologist.2017-0611. Epub 2018 Feb 7. No abstract available.

23.

Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care.

Ben-Aharon O, Magnezi R, Leshno M, Goldstein DA.

JAMA Oncol. 2018 Mar 1;4(3):326-332. doi: 10.1001/jamaoncol.2017.4445.

24.

The Collaborative Ocular Tuberculosis Study (COTS)-1 Report 3: Polymerase Chain Reaction in the Diagnosis and Management of Tubercular Uveitis: Global Trends.

Agarwal A, Agrawal R, Gunasekaran DV, Raje D, Gupta B, Aggarwal K, Murthy SL, Westcott M, Chee SP, Mccluskey P, Su Ling H, Teoh S, Cimino L, Biswas J, Narain S, Agarwal M, Mahendradas P, Khairallah M, Jones N, Tugal-Tutkun I, Babu K, Basu S, Carreño E, Lee R, Al-Dhibi H, Bodaghi B, Invernizzi A, Goldstein DA, Herbort CP, Barisani-Asenbauer T, González-López JJ, Androudi S, Bansal R, Moharana B, Mahajan S, Esposti S, Tasiopoulou A, Nadarajah S, Agarwal M, Abraham S, Vala R, Singh R, Sharma A, Sharma K, Zierhut M, Kon OM, Cunningham E, Nguyen QD, Pavesio C, Gupta V.

Ocul Immunol Inflamm. 2017 Dec 20:1-9. doi: 10.1080/09273948.2017.1406529. [Epub ahead of print]

25.

Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.

Dudnik E, Moskovitz M, Daher S, Shamai S, Hanovich E, Grubstein A, Shochat T, Wollner M, Bar J, Merimsky O, Zer A, Goldstein DA, Hammerman A, Cyjon A, Shechtman Y, Abu-Amna M, Flex D, Roisman LC, Peled N; Israel Lung Cancer Group.

Lung Cancer. 2018 Dec;126:217-223. doi: 10.1016/j.lungcan.2017.11.015. Epub 2017 Nov 23.

PMID:
29254746
26.

A Policy That Encourages Wastage of Expensive Medications-The JW Modifier.

Goldstein DA, Hirsch A.

JAMA Oncol. 2018 Feb 1;4(2):155-156. doi: 10.1001/jamaoncol.2017.3997. No abstract available.

PMID:
29222558
27.

A global comparison of the cost of patented cancer drugs in relation to global differences in wealth.

Goldstein DA, Clark J, Tu Y, Zhang J, Fang F, Goldstein R, Stemmer SM, Rosenbaum E.

Oncotarget. 2017 May 9;8(42):71548-71555. doi: 10.18632/oncotarget.17742. eCollection 2017 Sep 22.

28.

Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma.

Chen Q, Staton AD, Ayer T, Goldstein DA, Koff JL, Flowers CR.

Leuk Lymphoma. 2018 Jul;59(7):1700-1709. doi: 10.1080/10428194.2017.1390230. Epub 2017 Oct 25.

PMID:
29065744
29.

A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.

Goldstein DA, Gordon N, Davidescu M, Leshno M, Steuer CE, Patel N, Stemmer SM, Zer A.

J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx063.

PMID:
29059432
30.

Trajectories of Injectable Cancer Drug Costs After Launch in the United States.

Gordon N, Stemmer SM, Greenberg D, Goldstein DA.

J Clin Oncol. 2018 Feb 1;36(4):319-325. doi: 10.1200/JCO.2016.72.2124. Epub 2017 Oct 10.

PMID:
29016226
31.

Adjuvant Ipilimumab for Melanoma-The $1.8 Million per Patient Regimen.

Goldstein DA.

JAMA Oncol. 2017 Dec 1;3(12):1628-1629. doi: 10.1001/jamaoncol.2017.3123. No abstract available.

PMID:
28983562
32.

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.

Sarfaty M, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA.

Eur Urol. 2018 Apr;73(4):628-634. doi: 10.1016/j.eururo.2017.07.041. Epub 2017 Aug 12.

PMID:
28807351
33.

Fundus Autofluorescence Findings in Eyes With Birdshot Chorioretinitis.

Böni C, Thorne JE, Spaide RF, Ostheimer TA, Sarraf D, Levinson RD, Goldstein DA, Rifkin LM, Vitale AT, Jaffe GJ, Holland GN.

Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4015-4025. doi: 10.1167/iovs.17-21897.

34.

Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma.

Zeichner SB, Goldstein DA, Kohn C, Flowers CR.

J Gastrointest Oncol. 2017 Jun;8(3):513-523. doi: 10.21037/jgo.2016.04.03. Review.

35.

Reply to Á. Benedict et al.

Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR.

J Clin Oncol. 2017 Sep 10;35(26):3086-3087. doi: 10.1200/JCO.2017.74.5273. Epub 2017 Jul 17. No abstract available.

PMID:
28715248
36.

Multiple Sclerosis-Associated Uveitis.

Cunningham ET Jr, Pavesio CE, Goldstein DA, Forooghian F, Zierhut M.

Ocul Immunol Inflamm. 2017 Jun;25(3):299-301. doi: 10.1080/09273948.2017.1334469. No abstract available.

PMID:
28696171
37.

Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?

Goldstein DA, Bilal U, Prasad V.

Cancer. 2017 Oct 15;123(20):3872-3874. doi: 10.1002/cncr.30868. Epub 2017 Jun 29. No abstract available.

38.

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.

Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS.

Oncologist. 2017 Jun;22(6):694-699. doi: 10.1634/theoncologist.2016-0455. Epub 2017 Jun 7.

39.

Anterior Segment Optical Coherence Tomography Angiography for Identification of Iris Vasculature and Staging of Iris Neovascularization: A Pilot Study.

Roberts PK, Goldstein DA, Fawzi AA.

Curr Eye Res. 2017 Aug;42(8):1136-1142. doi: 10.1080/02713683.2017.1293113. Epub 2017 Apr 25.

40.

Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition.

Karass M, Grossniklaus E, Seoud T, Jain S, Goldstein DA.

Oncologist. 2017 May;22(5):623-625. doi: 10.1634/theoncologist.2016-0237. Epub 2017 Apr 19.

41.

Visualization of Photoreceptors in Birdshot Chorioretinopathy Using Adaptive Optics Scanning Laser Ophthalmoscopy: A Pilot Study.

Khanna S, Nesper PL, Koreishi AF, Goldstein DA, Fawzi AA.

Ocul Immunol Inflamm. 2017 Oct;25(5):610-620. doi: 10.1080/09273948.2017.1298819. Epub 2017 Mar 31.

PMID:
28362542
42.

Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.

Kohn CG, Zeichner SB, Chen Q, Montero AJ, Goldstein DA, Flowers CR.

J Clin Oncol. 2017 Apr 10;35(11):1194-1202. doi: 10.1200/JCO.2016.69.6336. Epub 2017 Feb 21.

43.

Financial toxicity in cancer care-Edging toward solutions.

Goldstein DA.

Cancer. 2017 Apr 15;123(8):1301-1302. doi: 10.1002/cncr.30555. Epub 2017 Feb 20. No abstract available.

44.

RETINAL CAPILLARY DENSITY IN PATIENTS WITH BIRDSHOT CHORIORETINOPATHY.

Roberts PK, Nesper PL, Goldstein DA, Fawzi AA.

Retina. 2018 Feb;38(2):387-394. doi: 10.1097/IAE.0000000000001543.

45.

Adalimumab for the treatment of uveitis.

LaMattina KC, Goldstein DA.

Expert Rev Clin Immunol. 2017 Mar;13(3):181-188. doi: 10.1080/1744666X.2017.1288097. Review.

PMID:
28140700
46.

Keeping the Name of Acute Posterior Multifocal Placoid Pigment Epitheliopathy.

Jampol LM, Goldstein DA, Fawzi AA.

JAMA Ophthalmol. 2017 Mar 1;135(3):186. doi: 10.1001/jamaophthalmol.2016.5334. No abstract available.

PMID:
28099970
47.

Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis.

Goldstein DA, Do D, Noronha G, Kissner JM, Srivastava SK, Nguyen QD.

Transl Vis Sci Technol. 2016 Dec 14;5(6):14. eCollection 2016 Dec.

48.

Opposition to Value-Based Cancer Care-Interests of Patients or Conflicts of Interest?

Goldstein DA.

Mayo Clin Proc. 2016 Dec;91(12):1842-1843. doi: 10.1016/j.mayocp.2016.10.001. No abstract available.

PMID:
27916159
49.

Decline in Ocular Toxoplasmosis over 40 Years at a Tertiary Referral Practice in the United States.

Hou JH, Patel SS, Farooq AV, Qadir AA, Tessler HH, Goldstein DA.

Ocul Immunol Inflamm. 2018;26(4):577-583. doi: 10.1080/09273948.2016.1246665. Epub 2016 Nov 28.

PMID:
27892751
50.

Economics of ramucirumab for metastatic colorectal cancer.

Zeichner SB, Kohn CG, Goldstein DA.

Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):733-745. Review.

PMID:
27828732

Supplemental Content

Loading ...
Support Center